News

DCR-PHXC is the only RNAi investigational therapy in development for the treatment of all types of PH, a family of severe, rare, inherited disorders of the liver that

The deal includes an upfront payment, and contingent clinical, development and regulatory milestone payments. AMAL Therapeutics is also eligible to receive up to €100m (£89.8m) based on the

Zejula achieved the primary endpoint of the PRIMA trial by showing a statistically significant improvement in progression-free survival irrespective of the participating women’s biomarker status, in comparison to

Ezallor Sprinkle is indicated as an adjunct to diet for the treatment of adult patients with hypertriglyceridemia, as an adjunct to diet for the treatment of adult patients

SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL). Sensorion initiated the Phase 2 clinical trial in this indication beginning of 2019 in

As per terms of the deal, Galapagos will secure $3.95bn (£3.5bn) upfront payment and $1.1bn (£874m) equity investment from Gilead. It intends to use the proceeds to expand

Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH

The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumours. The first patient was treated with SO-C101

The partnership will discontinue the evaluation of CNP520 in two pivotal phase II/III studies in the Alzheimer’s Prevention Initiative Generation Programme. According to Novartis, an evaluation of unblinded